GSK to Invest GBP1 Billion Tackling Infectious Diseases in Low-Income Countries
23 June 2022 - 09:43PM
Dow Jones News
By Joe Hoppe
GSK PLC said Thursday that it will invest 1 billion pounds
($1.23 billion) to accelerate research and development over the
next 10 years, targeting infectious diseases that
disproportionately affect lower-income countries.
The British pharmaceutical company, formerly known as
GlaxoSmithKline, said the investment will focus on new and
disruptive vaccines and medicines to prevent and treat malaria,
tuberculosis, HIV, neglected tropical diseases and anti-microbial
resistance. These account for more than 60% of the disease burden
in lower-income countries, the company said.
To deliver against its targets, GSK has formed a dedicated,
non-commercial global health unit, measuring success by its effects
on health alone without the concern of a commercial return on
investment. This includes global health research and development
hubs, which are advancing more than 30 potential new vaccines and
medicines, targeting 13 high-burden infectious diseases.
Shares at 1054 GMT were up 14.4 pence, or 0.8%, at 1,720.0
pence.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
June 23, 2022 07:28 ET (11:28 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
Historical Stock Chart
From Feb 2024 to Mar 2024
Gsk (LSE:GSK)
Historical Stock Chart
From Mar 2023 to Mar 2024